XNYS · Healthcare Plans
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$303.13+2.55%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
61/100
Positive
Score components
TickerWhale View
Cigna Group (The) scores 61 out of 100 overall, which we rate positive. Valuation is its strongest area and Risk its weakest.
What helps
- Technical
- Valuation
What to watch
- Quality & growth
- Risk
- Sentiment Signal
Quality & growth
30%44Weak
- Revenue growth 7.7%
- EPS growth 32.4%
Valuation
25%89Strong
- P/E 12.5
- EV/Sales 0.4
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
#171 by market cap in our coverage · ~67,700 employees · Listed 1982-04-01 · www.thecignagroup.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#42 / 139sector rank by TickerWhale Score
TickerWhale Score 61 vs sector average 54.6 (+6.4)
Revenue growth (industry)Top 50%
Gross margin (industry)Top 100%
Return on equity (industry)Top 25%
P/E (industry)Cheaper than 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
74/100Strong vs universe
Ranks 74th of 100 covered names on our technical composite — the composite itself scores 71/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 2 sell · 3 neutral of 8 votes
TickerWhale rates CI's technical setup strong — 74th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+7.3%
- vs 50-day+5.7%
Momentum
Mixed
- RSI (14)57 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength28· trending
- MACD (12,26,9)sell(histogram -0.939)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 2 sell · 3 neutral.
Result — 3 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)12.5
- P/S (TTM)0.3
- P/B1.9
- EV/EBITDA—
- EV/Sales0.4
- PEG0.38
Profitability & returns
- Gross margin8.8%
- Net margin2.3%
- ROE15.1%
- Debt/Equity0.75
Growth
- Revenue growth (YoY)7.7%
- EPS growth (YoY)32.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $80.0B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $274.9B | $247.1B | $195.3B |
| Gross profit | $25.6B | $26.0B | $25.2B |
| Operating income | $9.2B | $9.4B | $8.5B |
| Net income | $6.0B | $3.4B | $5.2B |
| EPS (diluted) | $22.18 | $12.12 | $17.39 |
| Free cash flow | $8.4B | $9.0B | $10.2B |
| Cash | $7.7B | $7.5B | $7.8B |
| Total debt | $31.5B | $32.0B | $30.9B |
| Equity | $41.7B | $41.0B | $46.2B |
| Net debt | $23.8B | $24.4B | $23.1B |
| Debt / equity | 0.75 | 0.78 | 0.67 |
| Liabilities / assets | 0.73 | 0.74 | 0.70 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CICurrentCigna Group (The) | 61 | 71 | 12.5 | — | 1.9 | 0.4 | $303.13 | +2.55% | +7.7% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.